Transcranial Focused Ultrasound Neuromodulation for Post-Stroke Motor Dysfunction
Transcranial Focused Ultrasound Neuromodulation in Post-Stroke Motor Dysfunction
This study aims to evaluate how transcranial focused ultrasound (tFUS) technology can promote neural network remodeling and functional recovery after stroke. By integrating signals from electroencephalography (EEG) and magnetic resonance imaging (MRI), the study will investigate how activating or inhibiting specific brain regions affects motor and cognitive recovery. The goal is to improve patients' motor and cognitive functions, reduce long-term disability, and enhance quality of life. The study also seeks to optimize stimulation parameters to maximize rehabilitation outcomes and explore the mechanisms underlying neuroprotection and functional reconstruction after stroke.
This is a case-control study involving a total of 60 participants. Participants will be ischemic stroke survivors aged 18-75 years, with first-ever stroke onset between 21 days and 6 months, stable vital signs, no consciousness disorders, and the ability to provide informed consent and cooperate with assessments. Eligible participants must have unilateral limb motor impairment, with an upper extremity modified Ashworth score ≤3, Brunnstrom stage II-V, and an upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60.
Participants will be assigned to either a neuromodulation group (receiving multi-modal neuromodulation targeting specific brain regions) or a control group (receiving sham stimulation or conventional treatment). Primary outcome measures include changes in FMA-UE scores, neuroimaging data (CT/MRI), EEG measurements (resting-state and task-state spectral power, functional connectivity), and laboratory markers (complete blood count, CRP, IL-6, S100β, BDNF). Secondary outcome measures include Brunnstrom stage, Ashworth grade, muscle strength, and patient comfort ratings. Safety will be monitored through blood routine tests, blood biochemistry, and coagulation function.
Statistical analysis will compare key indicator changes between the neuromodulation and control groups before and after intervention. Independent t-tests (for two groups) or ANOVA (for multiple groups) will be used to assess between-group differences, with non-parametric tests applied for data not following a normal distribution.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Xiao Zhang, Professor
- Número de telefone: +86 18612228766
- E-mail: zhangxiao@hit.edu.cn
Locais de estudo
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150001
- Harbin Institute of Technology
-
Contato:
- Xiao Zhang, Professor
- Número de telefone: +86 18612228766
- E-mail: zhangxiao@hit.edu.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- (1) Patients with a confirmed imaging diagnosis of first-ever ischemic stroke; (2) Unilateral limb motor involvement; (3) Modified Ashworth Scale (MAS) grade ≤3 for the upper extremity, Brunnstrom stage II-V, and upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60 (inclusive); (4) Age 18-75 years, onset within 21 days to 6 months, in the subacute or recovery phase; (5) Stable vital signs, no consciousness impairment, informed consent provided, ability to cooperate with clinical assessments, and approval obtained from the institutional ethics committee.
Exclusion Criteria:
- (1) Contraindications to MRI; (2) Infarction involving the thalamus; (3) Risk of intracranial hemorrhage; (4) Presence of intracranial metallic foreign bodies, cardiac pacemakers, or cochlear implants; (5) Unstable medical condition, severe cognitive impairment or psychiatric disorders rendering the patient unable to comprehend the study or cooperate with assessments; (6) Conditions affecting limb motor function, including fractures, joint contractures, or severe limb spasticity; (7) Current use of medications that alter cortical excitability.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Neuromodulation Group
Multimodal neuromodulation targeting specific neural regions in addition to conventional therapy.
|
The transcranial focused ultrasound stimulation device employed in this study is the NeuroFUS DPX-500, equipped with a 4-element transducer array and the BrainSight neuronavigation system.
Individualized modeling and target segmentation are performed using high-resolution structural MRI and CT images acquired at baseline.
Target planning and neuronavigation are conducted based on intracranial acoustic field simulation.
The total stimulation duration is 12 minutes, comprising 480 pulse trains with 0.5 seconds on and 1 second off, yielding a duty cycle of 20%.
|
|
Comparador Falso: Control Group
Sham stimulation in addition to conventional therapy.
|
The control group receives sham stimulation during the neuromodulation phase.
All procedural steps are identical to those of the experimental group, including neuronavigation positioning, application of coupling gel, and all other preparatory procedures; however, ultrasound stimulation is not activated.
Participants in the control group wear bone-conduction headphones to simulate and counteract acoustic confounding.
Group allocation information is blinded to participants.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Upper extremity Fugl-Meyer Assessment (UE-FMA) motor score
Prazo: Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)
|
Upper extremity motor function assessed by the Fugl-Meyer Assessment (motor subscale).
Total score ranges from 0 to 66, with higher scores indicating better motor function.
|
Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)
|
|
Resting-state EEG spectral power
Prazo: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Resting-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Task-state EEG spectral power
Prazo: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Task-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Resting-state fMRI fractional ALFF (fALFF)
Prazo: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
fALFF derived from resting-state functional MRI, the ratio of low-frequency power to whole-frequency power.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Resting-state fMRI regional homogeneity (ReHo)
Prazo: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
ReHo (Kendall's coefficient of concordance) from resting-state functional MRI, reflecting local synchronization of neuronal activity.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Resting-state fMRI functional connectivity (FC)
Prazo: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Functional connectivity between regions of interest derived from resting-state functional MRI (Fisher z-transformed correlation coefficients).
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Brunnstrom recovery stage of the affected upper limb
Prazo: Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
Motor recovery staged using the Brunnstrom approach, an ordinal scale from Stage 1 (flaccid, no movement) to Stage 6 (near-normal coordination), with higher stages indicating better motor recovery.
|
Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
|
Modified Ashworth Scale (MAS) grade of the affected upper limb
Prazo: Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
Muscle spasticity graded with the Modified Ashworth Scale, an ordinal scale with 6 levels (0, 1, 1+, 2, 3, 4); higher grades indicate greater spasticity (a worse outcome).
|
Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
|
Fractional anisotropy (FA) on diffusion tensor imaging (DTI)
Prazo: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
White-matter fractional anisotropy measured by diffusion tensor imaging.
Dimensionless (0-1), with higher values indicating greater directional coherence of water diffusion.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LSKY 2026-040-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .